GLP-1 and Pregnancy: What You Need to Know
GLP-1 medications are not safe during pregnancy or breastfeeding. If you are planning to conceive, you must stop your medication at least 2 months in advance. Meanwhile, an unexpected phenomenon is emerging: "Ozempic babies" — unplanned pregnancies from improved fertility. Here is everything you need to know.
Critical Safety Information
Do not take GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) during pregnancy or while breastfeeding. Animal studies have shown harmful effects on fetal development. If you become pregnant while on a GLP-1 medication, stop immediately and contact your healthcare provider.
Why You Must Stop Before Pregnancy
The science behind the pregnancy warnings is clear. Here is what the evidence shows and why the 2-month washout period matters.
Animal Study Findings
In animal reproductive toxicity studies, semaglutide caused embryo-fetal death, structural abnormalities (birth defects), and growth retardation in rats and rabbits at clinically relevant doses. Tirzepatide showed similar concerning results in animal studies, including skeletal variations and reduced fetal weight. While animal findings do not always translate directly to humans, the FDA considers these risks serious enough to warrant strong pregnancy warnings.
The Long Half-Life Problem
Semaglutide has a half-life of approximately 7 days — meaning it takes about 5 weeks for 97% of the drug to be eliminated from your body after the last dose. Tirzepatide has a half-life of about 5 days. The 2-month (semaglutide) and 1-month (tirzepatide) recommendations ensure the drug is essentially completely cleared from your system before conception, minimizing any potential exposure to the developing embryo during the critical first weeks of pregnancy.
No Human Safety Data
Pregnant women are excluded from clinical trials for ethical reasons, which means there are no controlled human studies on GLP-1 use during pregnancy. The limited data comes from pregnancies that occurred during clinical trials (before participants knew they were pregnant) and post-marketing surveillance. While many of these pregnancies resulted in healthy outcomes, the data is insufficient to confirm safety. The precautionary principle applies.
The "Ozempic Babies" Phenomenon
Since 2024, an increasing number of women have reported unexpected pregnancies while taking GLP-1 medications or shortly after starting them. Social media and news outlets have dubbed these "Ozempic babies." The phenomenon is real, but the mechanism is not what most people think.
Improved Fertility from Weight Loss
Obesity is one of the leading causes of female infertility. Excess weight disrupts the hormonal balance needed for regular ovulation — elevated insulin, estrogen stored in fat tissue, and chronic inflammation all interfere with reproductive function. Losing even 5-10% of body weight can restore normal ovulation in many women. GLP-1 medications produce 15-25% weight loss, which is more than enough to dramatically improve fertility in previously infertile women.
PCOS and Hormonal Rebalancing
Polycystic Ovary Syndrome (PCOS) — the most common cause of ovulatory infertility — is strongly associated with obesity and insulin resistance. GLP-1 medications improve both. As weight drops and insulin sensitivity improves, many women with PCOS begin ovulating regularly for the first time in years. Women who were told they would need IVF find themselves conceiving naturally after months on GLP-1 therapy.
Reduced Oral Contraceptive Efficacy
GLP-1 medications slow gastric emptying, which may affect the absorption of oral medications — including birth control pills. While this interaction is not definitively proven, the FDA has noted the possibility. Additionally, diarrhea and vomiting (common GLP-1 side effects) can reduce pill absorption. Women on GLP-1s who use oral contraceptives should consider adding a backup method or switching to non-oral contraception (IUD, implant, patch, ring).
The Timing Surprise
Many 'Ozempic baby' pregnancies happen in the first 3-6 months of treatment — before women have completed their weight loss journey and before they planned to conceive. The rapid hormonal improvement from early weight loss catches women off guard, especially those who had been trying to conceive unsuccessfully for years. This underscores the importance of reliable contraception for any woman of childbearing age who starts GLP-1 therapy and is not actively trying to become pregnant.
What to Discuss with Your OB/GYN
If you are a woman of childbearing age taking or considering GLP-1 medications, bring these topics to your next OB/GYN appointment.
Contraception While on GLP-1s
Discuss your current contraceptive method and whether it is reliable enough during GLP-1 therapy. If you use oral contraceptives, ask about potential absorption issues from slowed gastric emptying and GI side effects. Consider non-oral methods (IUD, implant, Depo-Provera, NuvaRing) that are not affected by GI absorption. If you are not actively trying to conceive, reliable contraception is essential.
Pre-Conception Planning
If you plan to become pregnant in the future, work with your OB/GYN and prescriber to create a timeline. Reach your goal weight, stabilize for a few months, then begin the washout period (2 months for semaglutide, 1 month for tirzepatide). Start prenatal vitamins during the washout period. Your prescriber may adjust other medications during this transition.
Fertility Assessment
If you have struggled with infertility, discuss the likelihood that GLP-1-mediated weight loss may improve your fertility. Be aware that improved fertility can happen quickly — sometimes within the first few months of treatment. If you are not ready to become pregnant, do not assume your previous infertility will continue to protect you.
Pregnancy Monitoring Plan
If you become pregnant while on a GLP-1 or shortly after stopping, your OB/GYN should be informed of your medication history. They may recommend additional monitoring including early dating ultrasound, first-trimester screening, and detailed anatomy scan. Most exposures result in healthy pregnancies, but extra vigilance is appropriate.
Postpartum GLP-1 Restart
After delivery, discuss when it is safe to restart your GLP-1 medication. If you plan to breastfeed, you will need to wait until after weaning (GLP-1s are not safe during breastfeeding). If formula feeding, you may be able to restart relatively soon after delivery. Your OB/GYN and prescriber should coordinate on the timing.
Breastfeeding and GLP-1 Medications
GLP-1 medications are not recommended during breastfeeding. Here is what the evidence shows.
Understanding the Fertility Connection
The connection between GLP-1 medications and improved fertility highlights a broader truth about obesity and reproductive health. Obesity affects fertility through multiple mechanisms: it disrupts the hypothalamic-pituitary-ovarian axis, increases insulin resistance (which drives androgen excess in PCOS), creates chronic low-grade inflammation that impairs implantation, and alters the uterine environment. When GLP-1 medications reverse these effects through weight loss and metabolic improvement, fertility can return remarkably quickly.
A 2025 retrospective analysis of over 40,000 women of childbearing age on GLP-1 therapy found that the unplanned pregnancy rate was approximately 2.5 times higher in the first 6 months of treatment compared to population norms. The effect was most pronounced in women with PCOS and those with BMI over 35 at baseline. This data reinforces the importance of proactive contraception counseling at the time GLP-1 therapy is initiated.
Planning Pregnancy After GLP-1 Therapy
For women who want to use GLP-1 therapy as a bridge to improved fertility, the recommended approach is: (1) achieve goal weight on GLP-1 therapy, (2) stabilize weight for 2-3 months at goal, (3) stop the medication and observe the 2-month washout period, (4) begin prenatal vitamins and pre-conception care during the washout, and (5) attempt conception after the washout is complete. This planned approach maximizes the fertility benefits of weight loss while minimizing any medication exposure risk to the developing embryo.
A Note for Couples
If both partners are overweight, simultaneous GLP-1 therapy may improve fertility from both sides. Male obesity is associated with lower testosterone, poorer sperm quality, and erectile dysfunction — all of which can improve with GLP-1-mediated weight loss. There are no known restrictions on male GLP-1 use during conception attempts, though this is an area where research is still emerging. Couples should discuss their GLP-1 use and family planning goals with their respective healthcare providers.
Frequently Asked Questions
How long before trying to conceive should I stop my GLP-1 medication?
The FDA recommends stopping semaglutide (Ozempic/Wegovy) at least 2 months before attempting pregnancy, and tirzepatide (Mounjaro/Zepbound) at least 1 month before. These timelines are based on the drug's elimination half-life — semaglutide has a half-life of approximately 1 week, meaning it takes about 5 weeks for 97% of the drug to clear your system. The 2-month recommendation provides an additional safety margin. Always work with your prescriber on the specific timeline for your situation.
What are 'Ozempic babies'?
'Ozempic babies' is a colloquial term for unplanned pregnancies that occur while taking GLP-1 medications or shortly after starting them. These pregnancies are not caused by the medication itself but rather by improved fertility resulting from weight loss and hormonal changes. Obesity is a leading cause of infertility, and losing even 5-10% of body weight can restore normal ovulation in women with PCOS or anovulation. Many women who were told they could not conceive find themselves pregnant after starting GLP-1 therapy.
Can GLP-1 medications cause birth defects?
Animal studies with semaglutide showed embryo-fetal toxicity, including structural abnormalities (birth defects) and growth problems, at doses relevant to human exposure. There is limited human data because pregnant women are excluded from clinical trials. Due to the animal findings, GLP-1 medications are classified as pregnancy risk — the potential risk to the fetus means they should not be taken during pregnancy. If you become pregnant while taking a GLP-1, stop the medication immediately and contact your OB/GYN.
Is it safe to breastfeed while taking a GLP-1 medication?
GLP-1 medications are not recommended during breastfeeding. Animal studies show that semaglutide is present in breast milk. There are no adequate studies in breastfeeding women to determine the effect on the nursing infant or on milk production. Given the potential for serious adverse effects in the infant and the long half-life of these drugs, the FDA recommends either discontinuing breastfeeding or discontinuing the medication. Discuss the risk-benefit with your OB/GYN and pediatrician.
Can GLP-1 medications affect male fertility?
Current evidence suggests that GLP-1 medications may actually improve male fertility. Obesity is associated with lower testosterone, poorer sperm quality, and erectile dysfunction. Weight loss from GLP-1 therapy can increase testosterone levels, improve sperm parameters, and enhance sexual function. No negative effects on male fertility have been identified in clinical trials. However, animal studies are limited, and men trying to conceive should discuss GLP-1 use with their urologist.
I just found out I'm pregnant and I'm on Ozempic. What do I do?
Stop taking Ozempic (or any GLP-1 medication) immediately and contact your OB/GYN. Do not wait for your next appointment — call them today. Most women who discover they are pregnant on a GLP-1 have healthy pregnancies, but early prenatal care is essential. Your OB/GYN may recommend additional monitoring, including early ultrasounds and potentially genetic screening. Do not panic — the most important thing is prompt action and ongoing medical care.
Does losing weight on GLP-1 medications improve IVF success?
Yes. Obesity is a well-documented barrier to IVF success. Women with BMI over 30 have lower implantation rates, higher miscarriage rates, and more complications during IVF cycles. Weight loss before IVF — including through GLP-1 therapy — can significantly improve outcomes. Many fertility clinics now recommend GLP-1-mediated weight loss as part of pre-IVF preparation. The key is stopping the medication well before the IVF cycle begins (at least 2 months for semaglutide).
Will I regain weight during pregnancy after stopping my GLP-1?
Some weight regain is normal and healthy during pregnancy — you are supposed to gain weight. The concern is not the pregnancy weight gain but rather the return of pre-treatment eating patterns. Some women find that the behavioral changes they developed while on GLP-1 therapy (smaller portions, reduced food noise) persist after stopping, while others experience a rapid return of appetite. Working with a nutritionist during pregnancy can help maintain healthy eating habits established during GLP-1 treatment.
Stay Informed About GLP-1 Safety
Our safety center tracks the latest research, FDA alerts, and clinical guidance on GLP-1 medications.
Medical Disclaimer: This guide is for informational purposes only and does not constitute medical advice. GLP-1 medications and pregnancy involve complex medical decisions that should be made with your healthcare providers. Always consult your OB/GYN and prescriber before making decisions about medication use during pregnancy planning, pregnancy, or breastfeeding. If you suspect you are pregnant and are taking a GLP-1 medication, stop the medication and contact your healthcare provider immediately.